Tom Moss
St Patrick Research Group In Basic Oncology
Laval, QC, Canada
Laval, QC, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Interpreting the Origins and Functions of Noncoding RNAs From the Ribosomal Genes.
Journal: Journal of cellular physiology
Published: February 21, 2025
The fragile X proteins' enigma: to be or not to be nucleolar.
Journal: Frontiers in cell and developmental biology
Published: June 13, 2024
TTF1 control of LncRNA synthesis delineates a tumor suppressor pathway directly regulating the ribosomal RNA genes.
Journal: Journal of cellular physiology
Published: March 15, 2024
Tao and Rap2l ensure proper Misshapen activation and levels during Drosophila border cell migration.
Tao and Rap2l ensure proper Misshapen activation and levels during Drosophila border cell migration.
Journal: Developmental cell
Published: July 21, 2023
HMG-boxes, ribosomopathies and neurodegenerative disease.
Journal: Frontiers in genetics
Published: May 19, 2023
Transcription factor UBF depletion in mouse cells results in downregulation of both downstream and upstream elements of the rRNA transcription network.
Journal: The Journal of biological chemistry
Published: March 17, 2023
A Legionella toxin exhibits tRNA mimicry and glycosyl transferase activity to target the translation machinery and trigger a ribotoxic stress response.
Journal: Nature cell biology
Published: November 08, 2022
Behavioral and molecular effects of Ubtf knockout and knockdown in mice.
Journal: Brain research
Published: June 02, 2022
Control of ribosomal RNA synthesis by hematopoietic transcription factors.
Journal: Molecular cell
Published: January 21, 2022
The human RNA polymerase I structure reveals an HMG-like docking domain specific to metazoans.
Journal: Life science alliance
Published: December 22, 2021
Ribosomal DNA promoter recognition is determined in vivo by cooperation between UBTF1 and SL1 and is compromised in the UBTF-E210K neuroregression syndrome.
Journal: PLoS genetics
Published: May 31, 2021
The chemotherapeutic agent CX-5461 irreversibly blocks RNA polymerase I initiation and promoter release to cause nucleolar disruption, DNA damage and cell inviability.
Journal: NAR cancer
Published: July 20, 2020
Last Updated: 09/26/2026